JP2021525248A5 - - Google Patents

Info

Publication number
JP2021525248A5
JP2021525248A5 JP2020565359A JP2020565359A JP2021525248A5 JP 2021525248 A5 JP2021525248 A5 JP 2021525248A5 JP 2020565359 A JP2020565359 A JP 2020565359A JP 2020565359 A JP2020565359 A JP 2020565359A JP 2021525248 A5 JP2021525248 A5 JP 2021525248A5
Authority
JP
Japan
Prior art keywords
region
compound
sequence number
seq
cdr1l
Prior art date
Application number
JP2020565359A
Other languages
English (en)
Japanese (ja)
Other versions
JP7293256B2 (ja
JP2021525248A (ja
JPWO2019226761A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033505 external-priority patent/WO2019226761A1/en
Publication of JP2021525248A publication Critical patent/JP2021525248A/ja
Publication of JP2021525248A5 publication Critical patent/JP2021525248A5/ja
Publication of JPWO2019226761A5 publication Critical patent/JPWO2019226761A5/ja
Priority to JP2023093659A priority Critical patent/JP7550922B2/ja
Application granted granted Critical
Publication of JP7293256B2 publication Critical patent/JP7293256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565359A 2018-05-23 2019-05-22 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 Active JP7293256B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023093659A JP7550922B2 (ja) 2018-05-23 2023-06-07 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675639P 2018-05-23 2018-05-23
US62/675,639 2018-05-23
PCT/US2019/033505 WO2019226761A1 (en) 2018-05-23 2019-05-22 Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093659A Division JP7550922B2 (ja) 2018-05-23 2023-06-07 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2021525248A JP2021525248A (ja) 2021-09-24
JP2021525248A5 true JP2021525248A5 (https=) 2022-05-30
JPWO2019226761A5 JPWO2019226761A5 (https=) 2022-05-30
JP7293256B2 JP7293256B2 (ja) 2023-06-19

Family

ID=66999900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565359A Active JP7293256B2 (ja) 2018-05-23 2019-05-22 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体
JP2023093659A Active JP7550922B2 (ja) 2018-05-23 2023-06-07 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023093659A Active JP7550922B2 (ja) 2018-05-23 2023-06-07 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体

Country Status (25)

Country Link
US (3) US11439637B2 (https=)
EP (2) EP4218762A3 (https=)
JP (2) JP7293256B2 (https=)
KR (1) KR102813281B1 (https=)
CN (2) CN112399848B (https=)
AU (1) AU2019274530B2 (https=)
BR (1) BR112020023704A2 (https=)
CA (1) CA3101050A1 (https=)
CY (1) CY1126060T1 (https=)
DK (1) DK3796912T5 (https=)
EA (1) EA202092830A1 (https=)
ES (1) ES2945214T3 (https=)
FI (1) FI3796912T3 (https=)
HR (1) HRP20230449T1 (https=)
HU (1) HUE061792T2 (https=)
IL (1) IL278853B2 (https=)
LT (1) LT3796912T (https=)
MX (1) MX420366B (https=)
PL (1) PL3796912T3 (https=)
PT (1) PT3796912T (https=)
RS (1) RS64189B1 (https=)
SG (1) SG11202011545YA (https=)
SI (1) SI3796912T1 (https=)
SM (1) SMT202300142T1 (https=)
WO (1) WO2019226761A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法
BR112020023756A2 (pt) 2018-05-23 2021-02-09 Celgene Corporation tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
JP2020103414A (ja) * 2018-12-26 2020-07-09 株式会社三洋物産 遊技機
RS67646B1 (sr) * 2019-01-09 2026-02-27 Celgene Corp Čvrsti oblici koji obuhvataju (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)metil) benzil)piperazin-1-il)-3-fluorobenzonitril i soli istog, kao i kompozicije koje obuhvataju i metode korišćenja istih
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
EP3819007B1 (en) 2019-11-11 2024-07-10 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
US20230114674A1 (en) * 2020-01-20 2023-04-13 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, and pharmaceutical composition and use thereof
JP2021133198A (ja) * 2020-02-28 2021-09-13 株式会社三洋物産 遊技機
JP2021133200A (ja) * 2020-02-28 2021-09-13 株式会社三洋物産 遊技機
JP2021133199A (ja) * 2020-02-28 2021-09-13 株式会社三洋物産 遊技機
CN116157125A (zh) * 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合
JP2023524068A (ja) 2020-04-30 2023-06-08 ブリストル－マイヤーズ スクイブ カンパニー サイトカイン関連有害事象を治療する方法
JP2021186294A (ja) * 2020-05-29 2021-12-13 株式会社三洋物産 遊技機
JP2022012088A (ja) * 2020-06-30 2022-01-17 株式会社三洋物産 遊技機
JP2022012090A (ja) * 2020-06-30 2022-01-17 株式会社三洋物産 遊技機
JP2022012089A (ja) * 2020-06-30 2022-01-17 株式会社三洋物産 遊技機
US12472176B2 (en) 2020-07-07 2025-11-18 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
CN119546329A (zh) 2022-04-11 2025-02-28 瑞泽恩制药公司 用于通用肿瘤细胞杀伤的组合物和方法
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포
WO2026059921A1 (en) * 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10683369B2 (en) * 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
US10238225B2 (en) * 2016-06-08 2019-03-26 Windor Enterprises, LLC Compression garment donning aid device, method, and kit
WO2018075820A2 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2021525248A5 (https=)
FI3796912T3 (fi) Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön
JPWO2019226761A5 (https=)
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP7126941B2 (ja) がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
JP2020500181A5 (https=)
JP2021513540A5 (https=)
JP2018506550A5 (https=)
JP2014533279A5 (https=)
JP2017522307A5 (https=)
JP2020502271A5 (https=)
JP2015534579A5 (https=)
JP7160533B2 (ja) 多発性骨髄腫（ｍｍ）の処置
JP2009519257A5 (https=)
US20200002428A1 (en) Treatment of c1013g/cxcr4-associated waldenstrom's macroglobulinemia with an anti-cxcr4 antibody
RU2020112490A (ru) Антитела из тяжелых цепей, связывающиеся с эктоферментами
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
JP2022189827A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2020533362A5 (https=)
JP2018529661A5 (https=)
JP2013504603A5 (https=)
JP2018533569A5 (https=)
EP3630177B1 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
JP2011505371A5 (https=)
JP2021511344A5 (https=)